Entamoeba

J. Enrique Salcedo-Sora
February 2014

Amoebiasis (prevalence)

Developed countries:

E. histolytica/E. dispar is 2.4% among immigrants

4% among travellers

27% among men who have sex with men

Most cases represent E. dispar colonization (only 4.6% of cases involved E. histolytica in some specific studies)

Developing countries:

Approximately 22%

For instance: Bangladesh 2.2% of preschool children have amoebic disentery.

Clinical presentation

Acute amoebiasis can present as diarrhoea or dysentery(*) with frequent, small and often bloody stools.

Chronic amoebiasis can present with gastrointestinal symptoms plus fatigue, weight loss and occasional fever.

Extraintestinal amoebiasis can occur if the parasite spreads to other organs, most commonly the liver where it causes amoebic liver abscess. Amoebic liver abscess presents with fever and right upper quadrant abdominal pain.

(*) Dysentery is defined as diarrhoea with visible blood in the stools. The most important and most frequent cause of acute dysentery is Shigella, especially S. flexneri and S. dysenteriae type 1. Other causes include Campylobacter jejuni, especially in infants, and, less frequently, Salmonella; dysentery caused by the latter agents is usually not severe. Enteroinvasive Escherichia coli are closely related to Shigella and may cause severe dysentery. However, infection with this agent is uncommon. Entamoeba histolytica cause dysentery in older children and adults, but rarely in children under 5 years of age.

Comparing two eukaryotic intestinal microorganisms

Trait Giardia Entamoeba
Protist YES YES
Zoonosis YES YES
Water&Food borne YES YES
Life cycle YES YES
Fermentation YES YES
Iron-Sulphur Clusters YES YES
Commensalism NO YES
Invasive Pathogenecity NO YES
Phagocytosis NO YES

Prevalence of E histolytica and E dispar in asymptomatic individuals

Population Number screened Technique (Stool) E. histolytica E. dispar
Asymptomatic individuals in South Africa 1381 Culture/isoenzyme analysis 1.00% 9.00%
Asymptomatic children in Bangladesh 680 ELISA 5.00% 12.00%
Asymptomatic individuals in 14 Philippine communities 1872 PCR 1.00% 7.00%
Asymptomatic individuals in Brazilian slum 564 ELISA 11.00% 9.00%
Asymptomatic individuals in Egypt 182 ELISA 21% 24.00%
Asymptomatic individuals in Greece 322 PCR and ELISA <1% 8.00%

Source:Stanley SL, Lancet 2003,361,1025-1034

Life cycle (faecal–oral route)

4-20% of asymptomatic individuals infected with E. hystolytica develop disease within a year. The onset is often gradual with several weeks of symptoms.

Trophozoites use a galactose and N -acetyl-D-galactosamine (Gal/GalNAc)-specific lectin to adhere to colonic mucins and thereby colonize the large intestine. Cytolysis is undertaken by the amoebapores, a family of at least three small peptides capable of forming pores in lipid bilayers. E histolytica trophozoites can also kill mammalian cells by induction of programmed cell death (apoptosis).

The trophozoite

The cyst

Amoebic colitis

Amoebic invasion through the mucosa and into the submucosal tissues is the hallmark of amoebic colitis.

Amoebic liver abscess

Amoebic liver abscess is 10 times as common in men as in women and is a rare disease in children. It is the most common extraintestinal manisfestation of amoebiasis. Once treated the liver recovers to normality and does NOT leave scars!

Diagnostics

Stool examination

Stool ELISA and PCR

Colonoscopy/flexible sigmoidoscopy

CT scan for suspected liver abscess

Treatment

Type Mechanism Adult dosage Clinical efficacy Adverse effects
Systemic
Metronidazole or tinidazole Activated in anaerobic organisms by reduction of the 5-nitro group 750 mg tid po or iv×5 to 10 days. For uncomplicated liver abscess (limited experience) 2·4 g qD po 2 days Or (tinidazole): 2 g qD po ×3 days Highly effective
Dehydroemetine Inhibits protein synthesis 1–1·5 mg/kg/day IM for up to 5 days Rapid amoebicidal activity
Type Mechanism Adult dosage Clinical efficacy Adverse effects
Luminal agents
Paromomycin Aminoglycoside—inhibit protein synthesis 30 mg/kg/day po in three divided doses for 5 to 10 days Poorly absorbed aminoglycoside with excellent safety profile
Diloxanide furoate Unknown 500 mg po tid×10 days Poorly absorbed antibiotic with excellent safety profile
Iodoquinol Unknown 650 mg po tid×20 days Poorly absorbed agent